Ecromeximab
Jump to navigation
Jump to search
Template:Short description Template:Cs1 config Template:Drugbox
Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.[1][2][3]
The drug was developed by Kyowa Hakko Kogyo Co., Ltd. As of December 2015 development had been discontinued.[4]
References
<templatestyles src="Reflist/styles.css" />
- ↑ Script error: No such module "citation/CS1".
- ↑ Clinical trial number NCT00679289 for "Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma" at ClinicalTrials.gov
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
Script error: No such module "Check for unknown parameters".